Micron, Twitter, Xenon News Today

Micron, Twitter, and Xenon are in the news today

by Alex Eppstein

Published on Mar 24, 2017 at 9:20 AM
Updated on Mar 24, 2017 at 10:46 AM

Stock futures are mixed this morning, as Wall Street keys in on President Trump's healthcare ultimatum. Among stocks in focus are chipmaker Micron Technology, Inc. (NASDAQ:MU), microblogging platform Twitter Inc (NYSE:TWTR), and drugmaker Xenon Pharmaceuticals Inc (NASDAQ:XENE). Here's a quick roundup of the headlines moving shares of MU, TWTR, and XENE.

Micron Eyes Post-Earnings Highs

MU is set to gap nearly 14% higher at the open, after an upbeat earnings report prompted a raft of bullish brokerage attention. Specifically, no fewer than eight analysts raised their price targets on the stock, with Needham setting the highest bar, at $50 -- territory not explored since 2000. After settling yesterday at $26.47, Micron Technology, Inc. could hurdle the round $30 level today, translating into a new two-year high. Even before today, the brokerage crowd was in MU's bullish corner, with 15 of 18 handing out a "buy" or better endorsement, and not a single "sell" to be found. Options traders have likewise taken a glass-half-full approach toward the shares.

Twitter Considers Tweetdeck Subscriptions

TWTR is mulling the creation of a subscription-based edition of its popular Tweetdeck interface. The news has the social media shares up 1.3%, after they settled Thursday at $14.93, down 8.4% year-to-date. Twitter Inc stock has few friends on Wall Street. Specifically, 96% of analysts rate the shares a "hold" or worse, while almost 10% of TWTR's total float is sold short.

Drug Data Drills Xenon Stock

XENE is pointed 47% lower in electronic trading, after the company's acne drug, XEN801, failed in a mid-stage study. Despite closing at $9.85 yesterday, and on a 49.6% annual lead, the stock could hit a record low if its pre-market losses materialize. This could also prompt bullish analysts to throw in the towel on Xenon Pharmaceuticals Inc. Currently, all four brokerage firms with coverage on XENE stock rate it a "strong buy."

Get a jump-start on the day's stock market news with Schaeffer's free Opening View newsletter.


a schaeffer's exclusive

PLAY TRENDS LIKE A PRO!

5 tips to leverage profits in this FREE insider report!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Trend Minting Millionaires -- But Who Is Really Paying?
Porter Stansberry is making a concerning prediction.
KEM Stocks Breaks Out Amid Buyout Buzz
Yageo group said it would buy Kemet in a $1.58 billion deal
FDA Delivers Another Blow to Solid Biosciences Stock
This is the second time a trial for the therapy has been placed on clinical hold in 2019
16-Hour "Jump Trades" Unlock New Profit Potential
Click to continue to advertiser's site.